Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amuvatinib + erlotinib
- Development stage
- Phase 1
- Lead developer
- Astex Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amuvatinib (MP470) is a small molecule receptor tyrosine kinase inhibitor that targets multiple kinases including PDGFR, c-Kit, and c-Met. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor marketed as Tarceva. The combination of amuvatinib and erlotinib has been studied for its additive effects in inhibiting tumor growth in prostate cancer models by targeting the HER family/PI3K/Akt pathway. This dual inhibition results in reduced phosphorylation of HER1, HER2, and HER3 receptors and downstream signaling through PI3K/Akt, leading to increased cytotoxicity and apoptosis in cancer cells[2][4]. Amuvatinib was developed by SuperGen (now Astex Pharmaceuticals), while erlotinib was developed by OSI Pharmaceuticals (acquired by Astellas Pharma). The combination has primarily been investigated preclinically for prostate cancer.
- Other names
- MP-470 + erlotinibamuvatinib + Tarceva
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)PDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on amuvatinib + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amuvatinib + erlotinib.